Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, & Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Asthmatic Patients With ABPA

NCT03960606 is registered in ClinicalTrials.gov with Pulmatrix Inc. as lead sponsor.

NCT NCT03960606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03960606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, & Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Asthmatic Patients With ABPA
Lead sponsor
Pulmatrix Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2019
Completion date
July 14, 2020
Enrollment
7 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

allergic bronchopulmonary aspergillosis